The latest news:

• NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma         This is great news.  The NCCN basically sets the standard of care for cancer treatments. The NCCN treatments classification is:

  NCCN Categories of Evidence and Consensus

  • Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.
  • Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.
  Not only does this set the standard of care as including Optune, but it should make it impossible for insurance companies to deny it.
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants